Skip to content

Web-based Validation Pelvic Floor Questionnaires

Validation of Electronic (Web-based and Smartphone) Administration of Measures of Pelvic Floor Dysfunction

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02724891
Enrollment
90
Registered
2016-03-31
Start date
2015-02-28
Completion date
2018-10-31
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Floor Dysfunction

Keywords

Pelvic Floor Dysfunction

Brief summary

Patient-reported outcomes are commonly used in healthcare. Examples include validated symptom-based questionnaires and health diaries. In the field of Female Pelvic Medicine and Reconstructive Surgery there are many questionnaires and diaries that have been validated for a paper-based administration. As technology is incorporated into delivery of medical care and research, investigators need to consider how to collect data electronically while ensuring that this new format is equivalent to the paper questionnaires they rely on. In this study, the investigators aim to validate a series of validated questionnaires and symptom diaries administered via the web and smartphone for a more streamlined care for the patients.

Detailed description

Health questionnaires and health diaries are two forms of patient-reported outcomes (PRO) commonly used in healthcare. Health questionnaires are often used as intake logs, discerning and recording the symptoms and severity of a problem at the time of presentation. Health diaries, in contrast, are ongoing logs which allow for mindful attention to symptoms and monitoring of response to therapy. Unfortunately, both types of PRO forms are often under-utilized or uninterpretable because they are collected on paper. Within urogynecology, PRO scales such as the Pelvic Floor Distress Inventory (PFDI), Pelvic Floor Impact Questionnaire (PFIQ), Bristol Stool Chart, Bladder Diaries and others are used ubiquitously. Their impact, however, is diminished by poor compliance and recall bias. The move towards electronic PRO measures would be endorsed by patients (who can track and interact with their data), physicians (who can track progress and study group outcomes) and by regulators (who want to ensure accurate and reproducible data collection). Electronic PRO tools, particularly on the patient's own device, would allow for increased rate of reporting through mobile availability, time stamping of data to prevent recall bias and reduction in data entry mistakes and costs. Study Procedures After informed consent is obtained, demographic data will be collected. Subjects will be administered the questionnaires either in paper or web-based or smartphone form based on a random number block scheme. At least two weeks later but prior to treatment they will complete the other form of the questionnaire. This can occur at their next office visit or can be completed at home. Subjects will be emailed and/or called by research staff to remind them to complete the second set of questionnaires.

Interventions

OTHERpaper form

questionnaires in paper form

OTHERweb/smartphone form

questionnaires in web/smartphone

Sponsors

University of Wisconsin, Madison
CollaboratorOTHER
University of Arkansas
CollaboratorOTHER
The Methodist Hospital Research Institute
CollaboratorOTHER
University of Calgary
CollaboratorOTHER
Columbia University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women at least 18 years of age presenting with pelvic floor dysfunction

Exclusion criteria

* Unable to repeat questionnaires or return to the office in 2 weeks * No access to computer/web or smartphone * Pregnancy (as gestational age will advance during 2 week time interval and symptoms may change)

Design outcomes

Primary

MeasureTime frameDescription
Test-retest reliability of PFDI-20 in the electronic formatminimum 2 week interval until subject receives treatment for the condition or up to one yearSubjects will complete the paper and either web-based or smartphone versions of the PFDI-20 with at least a 2 week interval between administration of the 2 versions.
Test-retest reliability of PFIQ-7 in the electronic formatminimum 2 week interval until subject receives treatment for the condition or up to one yearSubjects will complete the paper and either web-based or smartphone versions of the PFIQ-7 with at least a 2 week interval between administration of the 2 versions.
Test-retest reliability of PISQ-12 in the electronic formatminimum 2 week interval until subject receives treatment for the condition or up to one yearSubjects will complete the paper and either web-based or smartphone versions of the PISQ-12 with at least a 2 week interval between administration of the 2 versions.
Test-retest reliability of BSS in the electronic formatminimum 2 week interval until subject receives treatment for the condition or up to one yearSubjects will complete the paper and either web-based or smartphone versions of the BSS with at least a 2 week interval between administration of the 2 versions.

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026